Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is the recipient of a first or second deceased or living donor renal transplant (one kidney only)~* Subject must have at least one HLA-mismatch with the donor. HLA identical donor-recipient pairs are not eligible~* Subject understands either English or French~* If female and of child-bearing potential, subject has a negative pregnancy test and utilizes adequate contraceptive methods~Exclusion Criteria:~* Presence of donor specific antibody~* Subject who is currently participating in a study with investigational drug, or who has received investigational drug within three months prior to randomization. Observational studies are acceptable~* Subject who has lost a previous graft for immunological reasons less than one year from transplant~* Subject is pregnant or breastfeeding~* Subject receives a kidney lacking pre-implantation biopsy~* Subject has significant disease (e.g. malignancy or uncontrolled infection) or disability (e.g. cognitive defect) which prevents understanding of, or adherence to the protocol~* Subject who in the opinion of the Investigator, require ACEi/ARB therapy post-transplant for any indication~* Subject who requires induction with Thymoglobulin, Campath, antithymocyte globulin (ATG), antilymphocyte globulin (ALG) or any biological induction agent other than basiliximab. Unplanned post-transplant use of these prohibited drugs for clinical indications post-transplant is allowed~* Subject has plans to become pregnant within 2 years post-transplant~* Subject who has a positive T-cell or B-cell crossmatch. Subjects with a weakly positive B-cell cross-match that tests negative following DTT reduction are acceptable~* Subject who has a requirement for maintenance immunosuppressant therapy with the exception of low dose steroid or mycophenolate mofetil (MMF). A subject who is on low dose tacrolimus maintenance therapy will be eligible provided the tacrolimus is withheld at least 1 week prior to transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tacrolimus Standard Dose with ACEi/ARB (Type: ACTIVE_COMPARATOR): Participants receive a standard dose of tacrolimus with ACEi/ARB.
- Tacrolimus Standard Dose without ACEi/ARB (Type: ACTIVE_COMPARATOR): Participants receive a standard dose of tacrolimus without ACEi/ARB.
- Tacrolimus Low Dose with ACEi/ARB (Type: EXPERIMENTAL): Participants receive a low dose of tacrolimus with ACEi/ARB.
- Tacrolimus Low Dose without ACEi/ARB (Type: EXPERIMENTAL): Participants receive a low dose of tacrolimus without ACEi/ARB.

Based on this trial design, predict the completion outcome and termination type (if applicable).